{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/opioid-dependence/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 64b6d014-292e-425f-b4fb-3e7dd4d4b8d1 --><h2>Update</h2><!-- end field 64b6d014-292e-425f-b4fb-3e7dd4d4b8d1 -->","summary":null,"htmlStringContent":"<!-- begin item 354456fb-d05e-43ab-be3f-148c68cac5d6 --><!-- end item 354456fb-d05e-43ab-be3f-148c68cac5d6 -->","topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","lastRevised":"Last revised in October 2020","chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","fullItemName":"Management","slug":"management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e63e1346-068d-56e6-891b-85878800d361","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e7f9af1f-ed7f-5542-afcd-367a172ce0bf","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 3d2bf228-c101-4d2d-8593-8d0e26305d26 --><h3>New evidence</h3><!-- end field 3d2bf228-c101-4d2d-8593-8d0e26305d26 -->","summary":null,"htmlStringContent":"<!-- begin item b29a8e6a-7a68-4f1a-8c11-a750c5d1f0d7 --><!-- begin field e15efc7e-de21-425d-9e64-df456a8d55f6 --><h3>Evidence-based guidelines</h3><!-- end field e15efc7e-de21-425d-9e64-df456a8d55f6 --><!-- begin field 84a2a72c-33d7-45f7-9767-1247f1643901 --><ul><li>Mitchell, C., Dolan, N., Dursteler, K.M. (2020) Management of dependent use of illicit opioids. BMJ. <a href=\"https://www.bmj.com/\" data-hyperlink-id=\"b1f2a633-ac82-42f0-a630-ab880091cfac\">www.bmj.com</a> [<a href=\"https://www.bmj.com/content/368/bmj.m710.full\" data-hyperlink-id=\"fd601d61-5bf6-46b1-b2d0-ab880091cfc2\">Free full-text</a>]</li></ul><!-- end field 84a2a72c-33d7-45f7-9767-1247f1643901 --><!-- begin field dc936892-0f0c-4211-b491-84f38e1d83d0 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field dc936892-0f0c-4211-b491-84f38e1d83d0 --><!-- begin field cccf4642-48d9-49c4-b559-abf007b995a5 --><p>No new HTAs since 1 July 2019.</p><!-- end field cccf4642-48d9-49c4-b559-abf007b995a5 --><!-- begin field cab3b786-f3f0-4f5c-81e6-2924ea66ffe4 --><h3>Economic Appraisals</h3><!-- end field cab3b786-f3f0-4f5c-81e6-2924ea66ffe4 --><!-- begin field 3603f8db-2d58-4cf5-b64e-eac7ff428d79 --><p>No new economic appraisals relevant to England since 1 July 2019.</p><!-- end field 3603f8db-2d58-4cf5-b64e-eac7ff428d79 --><!-- begin field 31b9e34e-8c85-48da-ac70-ebbf5ab87375 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 31b9e34e-8c85-48da-ac70-ebbf5ab87375 --><!-- begin field 5b048800-05d5-406f-88e5-127ecedbcdc0 --><p>No new systematic reviews published since 1 July 2019.</p><!-- end field 5b048800-05d5-406f-88e5-127ecedbcdc0 --><!-- begin field 8c396431-62f0-4da7-bb2f-72d0774ea5ce --><h3>Primary evidence</h3><!-- end field 8c396431-62f0-4da7-bb2f-72d0774ea5ce --><!-- begin field 19101b75-7fe4-4ce1-8c71-be8272257080 --><p>No new randomized controlled trials published in the major journals since 1 July 2019.</p><!-- end field 19101b75-7fe4-4ce1-8c71-be8272257080 --><!-- end item b29a8e6a-7a68-4f1a-8c11-a750c5d1f0d7 -->","subChapters":[]},{"id":"ad586b27-0afa-53fc-a30f-920419dcde7c","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 3aba5cb0-e1da-420b-935e-bd83f4ed8606 --><h3>New policies</h3><!-- end field 3aba5cb0-e1da-420b-935e-bd83f4ed8606 -->","summary":null,"htmlStringContent":"<!-- begin item 68cb616f-9593-4d43-ad7e-a98b38633937 --><!-- begin field 0357a9c1-6394-455c-a697-85367b2b2ab0 --><p>No new national policies or guidelines since 1 July 2019.</p><!-- end field 0357a9c1-6394-455c-a697-85367b2b2ab0 --><!-- end item 68cb616f-9593-4d43-ad7e-a98b38633937 -->","subChapters":[]},{"id":"a7d930ee-b0c6-58e2-80fa-cfd93b070bc6","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field e57d7501-e7a7-4778-aa26-f22c655b3132 --><h3>New safety alerts</h3><!-- end field e57d7501-e7a7-4778-aa26-f22c655b3132 -->","summary":null,"htmlStringContent":"<!-- begin item 8584cdbc-0300-4805-830d-3baaa4dfa620 --><!-- begin field c350f893-53a7-4f9f-88dd-e4de6d052298 --><p>No new safety alerts since 1 July 2019.</p><!-- end field c350f893-53a7-4f9f-88dd-e4de6d052298 --><!-- end item 8584cdbc-0300-4805-830d-3baaa4dfa620 -->","subChapters":[]},{"id":"28dc5006-e943-5f96-83f1-b431da345759","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 810d8799-659f-41f2-9080-eb30f67df5f8 --><h3>Changes in product availability</h3><!-- end field 810d8799-659f-41f2-9080-eb30f67df5f8 -->","summary":null,"htmlStringContent":"<!-- begin item 6368bb44-65b6-4af6-ad94-0e4fcdaf6847 --><!-- begin field 7a928fe0-1af6-4c5b-bc04-75f153a59988 --><ul><li>Suboxone (buprenorphine/naloxone) sublingual film (various strengths) is licensed for use as a substitution treatment for opioid drug dependence for people aged over 15 years who have agreed to be treated, within a framework of medical, social, and psychological treatment. The intention of the naloxone component is to deter IV misuse. See more <a href=\"https://www.medicines.org.uk/emc/product/11650/smpc\" data-hyperlink-id=\"b4abef42-c0e2-4e20-a9b5-ac1000b237ea\">here</a>.</li></ul><!-- end field 7a928fe0-1af6-4c5b-bc04-75f153a59988 --><!-- end item 6368bb44-65b6-4af6-ad94-0e4fcdaf6847 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}